Humana Inc. $HUM Stock Holdings Lifted by Geode Capital Management LLC

Geode Capital Management LLC raised its position in shares of Humana Inc. (NYSE:HUM) by 1.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,130,829 shares of the insurance provider’s stock after purchasing an additional 57,267 shares during the period. Geode Capital Management LLC owned 2.60% of Humana worth $762,233,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock worth $3,697,222,000 after buying an additional 1,143,662 shares during the last quarter. AQR Capital Management LLC lifted its stake in Humana by 3,257.5% in the first quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider’s stock valued at $307,624,000 after acquiring an additional 1,127,973 shares during the last quarter. Leith Wheeler Investment Counsel Ltd. grew its position in Humana by 661.7% in the second quarter. Leith Wheeler Investment Counsel Ltd. now owns 1,038,703 shares of the insurance provider’s stock worth $253,942,000 after acquiring an additional 902,340 shares in the last quarter. Nuveen LLC acquired a new position in shares of Humana during the 1st quarter worth $171,220,000. Finally, Dodge & Cox increased its stake in shares of Humana by 5.5% during the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock worth $2,845,830,000 after purchasing an additional 557,175 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Trading Down 1.6%

Humana stock opened at $236.75 on Friday. Humana Inc. has a 52 week low of $206.87 and a 52 week high of $315.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The firm has a market capitalization of $28.47 billion, a PE ratio of 18.17, a PEG ratio of 1.71 and a beta of 0.42. The business’s 50-day simple moving average is $272.46 and its 200-day simple moving average is $258.23.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. The firm had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company’s revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm posted $4.16 EPS. Equities research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.5%. Humana’s payout ratio is 33.18%.

Analysts Set New Price Targets

HUM has been the subject of several analyst reports. Morgan Stanley reduced their price objective on shares of Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a research note on Thursday, July 31st. Bank of America raised their target price on Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a report on Friday, October 10th. The Goldman Sachs Group initiated coverage on Humana in a research note on Tuesday, October 14th. They set a “sell” rating and a $235.00 price target for the company. Evercore ISI assumed coverage on Humana in a report on Monday, September 22nd. They set an “in-line” rating and a $295.00 price objective on the stock. Finally, Truist Financial cut their price objective on Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $298.39.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.